A Single Center, Randomized, Open-label, Cross-over Exploratory Study to Evaluate the Pharmacodynamic and Pharmacokinetic Response to a Subcutaneous Administration or Oral Administration of Furosemide in Subjects With Heart Failure Presenting With Chronic Fluid Overload
Latest Information Update: 06 Mar 2023
Price :
$35 *
At a glance
- Drugs Furosemide (Primary) ; Furosemide (Primary)
- Indications Heart failure
- Focus Therapeutic Use
- Acronyms FUROPHARM-HF; scFUROPHARM
- Sponsors scPharmaceuticals
- 30 Jun 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov
- 14 Oct 2014 New trial record